Clinical Trial: NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Oncternal Therapeutics, Inc |
| Information Provided By: | Oncternal Therapeutics, Inc |
| Last Update Posted: | 2025-02-12 |
Study Overview
Brief Summary
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
Official Title
Conditions
Intervention / Treatment
- Drug: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- Drug: Cirmtuzumab (300mg) plus Ibrutinib
- Drug: Cirmtuzumab (600 mg) plus ibrutinib
- Drug: Cirmtuzumab (RDR) plus ibrutinib
- Drug: Cirmtuzumab plus ibrutinib
- Drug: Ibrutinib alone
Other Study ID Numbers
- CIRM-0001 (CIRLL)
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Oncternal Therapeutics, Inc |
| Information Provided By: | Oncternal Therapeutics, Inc |
| Last Update Posted: | 2025-02-12 |
Study Overview
Brief Summary
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
Official Title
Conditions
Intervention / Treatment
- Drug: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- Drug: Cirmtuzumab (300mg) plus Ibrutinib
- Drug: Cirmtuzumab (600 mg) plus ibrutinib
- Drug: Cirmtuzumab (RDR) plus ibrutinib
- Drug: Cirmtuzumab plus ibrutinib
- Drug: Ibrutinib alone
Other Study ID Numbers
- CIRM-0001 (CIRLL)